[Alterations of the plasma ribonuclease activity in female wistar rats under the conditions of combined therapy of the ovary carcinoma (author's transl)].
The authors have analysed the influence exercised by the combined therapy of the ovary carcinoma on the plasma ribonuclease activity in Wistar rats. The medicaments "Proresid", "VM-26", and "Methotrexat" together with a percutaneous irradiation of the abdomen did not alterate perceptibly the enzyme activity during the experiment, but there was a considerable reduction of the enzyme activity after an application of "Endoxan", "Adriblastin" and "Methotrexat" with subsequent administration of "Leukovorin". The most violent ribonuclease suppression, however, was obtained by an intraperitoneal instillation of radiogold and a fractioned percutaneous irradiation of the abdomen with intercalated administration of "Endoxan".
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D002955:Leucovorin / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011033:Podophyllin / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000627:therapeutic use; D051381:Rats; D012260:Ribonucleases / Q000097:blood*
D004317:Doxorubicin; D003520:Cyclophosphamide; D011033:Podophyllin; D012260:Ribonucleases; D011034:Podophyllotoxin; D002955:Leucovorin; D008727:Methotrexate
Veränderungen der Plasmaribonuklease-Aktivität bei weiblichen Wistar-Ratten unter den Bedingungen der Kombinationstherapie des Ovarialkarzinoms.